A combined preparation of animal origin, contains a glycosaminoglycan-peptide complex. The effect of the drug is due to the combined effect of its active components. Normalizes metabolism in cartilage hyaline tissue: enhances the biosynthesis of sulfated mucopolysaccharides and collagen, stimulates the regeneration of articular cartilage, reduces enzyme activity and inhibits catabolic processes in cartilage tissue.
Indications - Degenerative-dystrophic diseases of the joints: gonarthrosis, arthrosis of the interphalangeal joints, coxarthrosis, spondylosis, spondyloarthrosis, meniscopathy, chondromalacia of the patella.
The drug is administered deeply intramuscularly, on the first day - 0.3 ml, on the second day - 0.5 ml and then 1-2 ml 3 times a week.
A course of 25 injections of 1 ml or 15 injections of 2 ml (over 5-8 weeks) is repeated 2-4 times a year for many years.
Composition per 1 ml:
Rumalon, liquid extract substance* - 1 ml.
* Composition of the extract substance:
active substance:
costal cartilage extract and calf bone marrow extract (in a ratio of 1:2 to 1:4), containing glycosaminoglycan-peptide complex - 2.25 mg
excipients: metacresol - 2.60 mg, 0.1 M hydrochloric acid solution - up to pH = 6.5 - 7.5, water for injection - up to 1 ml.
Excipients: 0.1 M hydrochloric acid solution - up to pH = 6.5 - 7.5.
Contraindications
- hypersensitivity to the components of the drug,
- rheumatoid arthritis,
- age up to 18 years,
- pregnancy, breastfeeding period,
- use in women of reproductive age who do not comply with reliable methods of contraception.
Use during pregnancy and breastfeeding
The use of the drug during pregnancy and breastfeeding is contraindicated (due to the lack of information on the use of the drug in these groups of patients).
The drug Rumalon® can be used simultaneously with non-steroidal anti-inflammatory drugs and glucocorticosteroids.
When used simultaneously with indirect anticoagulants, antiplatelet agents and fibrinolytics, their effect may be enhanced